![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Daclatasvir Plus Sofosbuvir Plus Ribavirin for
12 or 16 Weeks in Treatment-Experienced Patients with
HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Hézode C,1 Dore GJ,2 Pianko S,3 Pol S,4 Stuart K,5 Thompson A,4
Tse E,6 Bhore R,7 Jimenez-Exposito MJ7
1Hépato-gastro-entérologie, CHU Henri-Mondor, Créteil, France; 2St. Vincent's Hospital and Kirby Institute, Sydney, Australia; 3Monash Medical Centre, Clayton, Australia; 4Hôpital Cochin, Paris, France; 5Gallipoli Medical Research Foundation, Greenslopes, Australia; 6Royal Adelaide Hospital, Adelaide, Australia; 7Bristol-Myers Squibb Research & Development, Princeton, NJ, USA
![EASL1](../images/042016/042016-3/EASL1.gif)
![EASL2](../images/042016/042016-3/EASL2.gif)
![EASL3](../images/042016/042016-3/EASL3.gif)
![EASL4](../images/042016/042016-3/EASL4.gif)
![EASL5](../images/042016/042016-3/EASL5.gif)
![EASL6](../images/042016/042016-3/EASL6.gif)
![EASL7](../images/042016/042016-3/EASL7.gif)
![EASL8](../images/042016/042016-3/EASL8.gif)
![EASL9](../images/042016/042016-3/EASL9.gif)
![EASL10](../images/042016/042016-3/EASL10.gif)
![EASL11](../images/042016/042016-3/EASL11.gif)
![EASL12](../images/042016/042016-3/EASL12.gif)
![EASL13](../images/042016/042016-3/EASL13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|